SHAREHOLDER ALERT: Investigation of Avidity (RNA) Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA) complied with federal securities laws. On September 27, 2022, Avidity announced that the U.S. Food and Drug Administration has placed a partial clinical hold on new participant enrollment in its Phase 1/2 MARINA clinical trial following a serious adverse event. After this announcement, the Company's stock price dropped.

If you purchased Avidity stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/avidity/ to discuss your legal rights. 

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT: 
Corey Holzer, Esq. 
(888) 508-6832 (toll-free) 
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138908